Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
Interest Income Expense
Verona Pharma PLC
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Verona Pharma PLC
NASDAQ:VRNA
|
Interest Income Expense
$12.6m
|
CAGR 3-Years
132%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Interest Income Expense
-£641m
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
AstraZeneca PLC
LSE:AZN
|
Interest Income Expense
-$1.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
Indivior PLC
LSE:INDV
|
Interest Income Expense
$9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Interest Income Expense
-$67m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Interest Income Expense
-£21m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-14%
|
See Also
What is Verona Pharma PLC's Interest Income Expense?
Interest Income Expense
12.6m
USD
Based on the financial report for Dec 31, 2023, Verona Pharma PLC's Interest Income Expense amounts to 12.6m USD.
What is Verona Pharma PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
43%
The average annual Interest Income Expense growth rates for Verona Pharma PLC have been 132% over the past three years , 43% over the past five years .